Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Nipro Pharma Likely to Face Business Improvement Order over Violations
February 24, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- MOF to Work with Industry to Boost Drug Discovery, Minister Says on Trade Deficit
February 22, 2023
- MHLW to Launch SaMD Working Group to Compile Opinions by Summer
February 22, 2023
- Consider Special Characteristics of Patches If Govt Is to Revise LLP Pricing Rules: LDP League
February 21, 2023
- LDP Project Team Hears Report on Expert Panel Debate; Chair Voices Difficulty around Political Intervention
February 21, 2023
- LDP’s Generic League Aiming to Finalize Proposal in April for Honebuto Policy
February 21, 2023
- Avigan Used Improperly for 429 Patients in Observational Study: MHLW
February 21, 2023
- AZ’s Evusheld Gets Label Update on Repeat Dosing
February 21, 2023
- MHLW to Launch Fact-Finding Study on COVID-19 Vaccine Reactions
February 20, 2023
- Lilly’s Ulcerative Colitis Med Up for MHLW Panel Review on March 3
February 20, 2023
- Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
- Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
February 16, 2023
- MHLW Approves First Generics for Azilva, Revlimid towards June Listing
February 16, 2023
- Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
- 5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
- Darzquro to Escape CEA-Based Price Tweaks, Padcev Faces Cuts
February 16, 2023
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
- PM Vows Collab with Pharma for Drug Discovery; Health Minister on Relyvrio
February 16, 2023
- Daiichi Sankyo’s Nasal Flu Vaccine Up for MHLW Panel Review on February 27
February 15, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…